Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with B-cell acute lymphoblastic leukemia (a type of blood cancer) where testing of the bone marrow shows no detectable cancer cells remaining (less than 0.01%), AND who fall into at least one of these groups: their cancer came back and then went into remission again; they have a very high-risk form of the disease heading toward a stem cell transplant in their first remission; or low but detectable levels of cancer were still found at the end of an early treatment phase.
• People who have a suitable donor available — either an unrelated donor or a partially matched family member (haploidentical donor).
• People aged 25 or younger at the time of joining the study.
• People who have a reasonable level of physical functioning, measured by standard scoring scales used for their age group (confirm with trial site).
• People whose heart, lungs, liver, kidneys, and nervous system are functioning well enough to meet specific medical thresholds, confirmed by tests done within 14 days of registration.
• People whose cancer came back after a previous stem cell transplant may still be eligible, provided there are no signs of a transplant-related immune reaction (called graft-versus-host disease) and all transplant immune-suppressing medications have been stopped for at least 7 days.
• People who have completed other immune-based treatments (such as CAR T-cell therapy or cancer vaccines) at least 42 days before joining, not including a specific drug called blinatumomab.
• People who had prior radiation to the brain or spine at least 90 days before joining, and who will not receive that type of radiation during the study.
• People who are sexually active and able to become pregnant, or who could father a child, and who agree to use appropriate contraception during treatment and for 2 months afterward.
• People (or their guardians) who are willing and able to give voluntary written consent to participate.
• People who have already been enrolled in a related study called the Blinatumomab Bridging Therapy (BBT) Trial.

Who may not be able to join:

• People whose cancer has spread outside the bone marrow, or who have tumor masses forming in tissues (sometimes called chloromas).
• People currently receiving other cancer treatments not specified by this study's plan.
• People who have an active infection (bacterial, viral, fungal, or other) that is not yet under control despite appropriate treatment; people with a possible fungal infection must have completed at least 2 weeks of antifungal treatment and have no remaining symptoms.
• People who are pregnant or breastfeeding, as the treatments used carry known risks to a fetus; a pregnancy test is required within 7 days before registration for anyone who could become pregnant.
• People who have a known allergy to any of the medications used in this study.
• People who are currently participating in another Phase 1 or Phase 2 clinical treatment study.
• People who have another active cancer in addition to B-cell acute lymphoblastic leukemia.

Important: Always verify eligibility with the trial site directly before applying.